Appendiceal cancer (appendix cancer) refers to malignant tumors that arise in the vermiform appendix. These neoplasms are uncommon and encompass a variety of histologic types with very different behavior. Because the appendix is small and often removed for suspected appendicitis, many appendiceal tumors are discovered incidentally during surgery or after pathological examination of an appendectomy specimen. For a general overview of rare tumor types see resources on appendiceal malignancies.
Types and pathology
Appendiceal tumors include several distinct categories, each with its own natural history and treatment implications. Common groups are:
- Neuroendocrine tumors (carcinoids) — often small, sometimes clinically silent, and generally less aggressive when tiny; behavior correlates with size and invasion depth.
- Mucinous neoplasms — range from low-grade appendiceal mucinous neoplasm (LAMN) to high-grade variants; they can produce copious mucin and, if they perforate, may seed the peritoneal cavity causing pseudomyxoma peritonei.
- Adenocarcinomas — including colonic-type and signet-ring cell variants; these behave more like colorectal cancer and may present at a more advanced stage.
- Goblet cell carcinoma (also called goblet cell carcinoid/carcinoma) — a mixed neuroendocrine and glandular tumor with intermediate to aggressive behavior.
- Less common — primary lymphomas, gastrointestinal stromal tumors (GIST), and other rare histologies can also arise in the appendix.
Clinical presentation and diagnosis
Symptoms are variable. Many patients present with signs indistinguishable from acute appendicitis: right lower abdominal pain, fever, or nausea. Others are asymptomatic and tumors are found incidentally. When mucinous tumors rupture or spread within the abdomen, patients can develop progressive abdominal distension from mucinous ascites (pseudomyxoma peritonei) or bowel obstruction.
Diagnosis typically combines imaging (ultrasound, CT, MRI) and pathological review. Cross-sectional imaging helps identify an appendiceal mass, wall thickening, or mucinous collections; colonoscopy may miss isolated appendiceal tumors because the lesion is confined to the appendiceal lumen. Blood tumor markers such as CEA or CA 19-9 are sometimes elevated but are not specific. For guidance on diagnostic pathways and imaging, see diagnostic resources.
Treatment and prognosis
Treatment depends on histology, tumor size, and whether disease has spread. Options include:
- Simple appendectomy — may be sufficient for small, localized neuroendocrine tumors or certain benign-appearing lesions.
- Right hemicolectomy — recommended for larger or invasive adenocarcinomas and some neuroendocrine tumors based on risk factors.
- Cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC) — used for mucinous tumors that have seeded the peritoneum (pseudomyxoma peritonei) to remove visible disease and treat microscopic implants.
- Systemic chemotherapy or targeted approaches — applied when tumors have high-grade features or distant spread, often following principles used for colorectal or neuroendocrine tumors.
Prognosis varies widely: low-grade mucinous lesions and small neuroendocrine tumors can have favorable outcomes, while high-grade adenocarcinomas and signet-ring variants carry a poorer prognosis. Close collaboration between surgeons, pathologists, and oncologists is important to determine optimal management.
Distinctions and notable facts
It is important to distinguish primary appendiceal cancer from metastatic deposits in the appendix. Tumors from the colon, breast, ovary and other organs can metastasize to the appendix; for example, breast cancer metastases to the appendix have been reported. Primary lymphomas may also involve the appendix (see information on lymphomatous involvement), and gastrointestinal stromal tumors are another rare primary lesion. Because clinical behavior, staging and treatment differ by histology, pathology review and appropriate staging studies are essential.
Given their rarity and heterogeneous biology, appendiceal tumors are best managed in centers experienced with peritoneal surface malignancies and multidisciplinary care. Early recognition, accurate histologic classification, and tailored surgery improve the chances of effective treatment and long-term control.